This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Metformin and cardiovascular (CV) risk

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • a systematic review investigated the cardiovascular outcomes in trials of oral diabetes drugs or placebo in type 2 diabetes
    • treatment with metformin hydrochloride was associated with a decreased risk of cardiovascular mortality (pooled OR, 0.74; 95% CI, 0.62-0.89) compared with any other oral diabetes agent or placebo; the results for cardiovascular morbidity and all-cause mortality were similar but not statistically significant

Reference:

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page